Globalisation on pause? How scaleups can navigate today's uncertainty9:30 am - 10:30 am
BGF Quoted backs Netcall plc
BGF Quoted has provided £7m in funding to AIM-listed Netcall plc, a provider of technology solutions that help businesses better engage with their customers. The funding has been used to support Netcall’s acquisition of MatsSoft Limited, a cloud-based software provider. The investment was transacted via BGF’s most recently opened regional office in Milton Keynes.
Headquartered in Hemel Hempstead, Netcall has more than 700 customers in the private and public sector including NHS Acute Health Trusts, BT, Lloyds Banking Group, Axa and Interflora. The company’s product suite incorporates omni-channel contact centre, workforce optimisation and business process management, delivered through its integrated platform, Liberty.
Bedford-headquartered MatsSoft has a low-code software platform used by approximately 60 customers globally including Vodafone, Nationwide Building Society and ITV. The acquisition will increase Netcall’s cloud presence and provide access to the fast growing low-code market.
The funding into Netcall was led by Mark Nunny, Sarah Ledwidge, Tom Jenkins and Paul Stevens.
Henrik Bang, CEO, Netcall said: “We are taking a big step forward in delivering on our strategy and are thrilled to have MatsSoft as a part of Netcall. We see a great opportunity offering the MatsSoft capabilities to our customers as well as expanding into new markets, which was made possible with the funding provided by BGF.”
BGF’s Tom Jenkins said: “Netcall has a strong track record on AIM and a talented management team, led by Henrik. This acquisition takes the business into the low-code market, which provides an interesting opportunity for further growth. We are delighted to support Netcall with this funding.”
Business funding news
OSL receives £3.5 million follow-on investment as impressive growth continues
BGF has invested a further £3.5 million into leading counter-drone technologies business Operational Solutions Limited (OSL), taking its total investment…
ViaNautis raises £20 million Series A financing to drive the next generation of genetic nanomedicines
ViaNautis Bio, a ground-breaking nanomedicine company at the forefront of genetic therapies, has completed its Series A funding round, raising…